MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Oragenics Gross Profit 2011-2026 | OGEN
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Oragenics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 694 K | 570 K | 689 K | 453 K | 731 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 731 K | 453 K | 627 K |
Quarterly Gross Profit Oragenics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 172 K | - | - | - | 196 K | - | 127 K | 178 K | 135 K | - | 140 K | 81 K | 112 K | - | 100 K | 144 K | 182 K | - | 216 K | 18.8 K | 255 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 255 K | 18.8 K | 147 K |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K |  USA |
 |
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
5.51 M | - | 2.54 % | $ 160 B |  France |
 |
Esperion Therapeutics
ESPR
|
225 M | $ 3.13 | 0.39 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
935 M | $ 45.86 | 3.23 % | $ 12.5 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | USA |
 |
Fortress Biotech
FBIO
|
31 M | $ 2.51 | 2.03 % | $ 70 M | USA |
 |
Galapagos NV
GLPG
|
896 M | $ 28.95 | 1.97 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
-182 M | $ 27.7 | 0.59 % | $ 17.1 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
2.79 B | $ 8.37 | 1.2 % | $ 6.83 B |  Spain |
 |
InflaRx N.V.
IFRX
|
-7.24 M | $ 2.44 | 24.11 % | $ 152 M | Germany |
 |
Immuron Limited
IMRN
|
524 K | $ 0.81 | 2.15 % | $ 6.7 M |  Australia |
 |
Ionis Pharmaceuticals
IONS
|
1.12 B | $ 76.26 | 1.34 % | $ 12.2 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - |  Russia |
 |
Kamada Ltd.
KMDA
|
76.4 M | $ 8.25 | 0.49 % | $ 260 M |  Israel |
 |
INmune Bio
INMB
|
-10.9 K | $ 1.55 | 0.65 % | $ 38.4 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
89 K | $ 12.98 | -3.49 % | $ 1.72 B | Australia |
 |
ACADIA Pharmaceuticals
ACAD
|
473 M | $ 22.93 | 2.6 % | $ 3.8 B | USA |
 |
Liquidia Corporation
LQDA
|
0.502 | $ 42.33 | 5.48 % | $ 3.64 B | USA |
 |
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.03 M | $ 3.55 | 1.43 % | $ 5.84 M | Israel |
 |
Aeterna Zentaris
AEZS
|
2.65 M | - | 5.93 % | $ 314 M |  Canada |
 |
MannKind Corporation
MNKD
|
35.1 M | $ 4.01 | 40.03 % | $ 1.23 B | USA |
 |
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M | Germany |
 |
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
1.56 K | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-523 K | - | -11.43 % | $ 502 K | USA |